This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Prompt reperfusion of ischemic tissue is critical for restoring normal function, but it can precipitate a progressive destruction of reversibly damaged cells, leading to paradoxical tissue dysfunction and necrosis. This reperfusion injury has a multifactorial etiology but it is associated with a fulminating infiltration of leukocytes, with subsequent release of cytotoxic mediators, into the previously ischemic tissue.1,2 An early event in the reperfusion process is the adhesion and accumulation of neutrophils. Although this is expected as part of the healing process, it can be fulminating due to a vascular endothelium that has been activated by inflammatory mediators such as platelet activating factor (PAF) and reactive oxygen metabolites. Accumulation of neutrophils, together with red blood cells and platelets, can lead to capillary plugging3 and a reduction in microvascular blood flow, resulting in focal areas of stasis. Once infiltrated into tissues, neutrophils are capable of releasing various proteases, lipid-derived mediators, and reactive oxygen species that can injure potentially salvageable cells.
The adhesion and migration of neutrophils are orchestrated by several classes of cell surface glycoproteins. These include the leukocyte integrins(CD11/CD18), the immunoglobulin supergene family [intercellular adhesion molecule-1 (ICAM-1); vascular cell adhesion molecule-1 (VCAM-1)], and the selectins (L-, P-, and E-selectin).4 Studies employing monoclonal antibodies (MAbs) directed at specific members of these various pathways have been instrumental in demonstrating the importance of neutrophils in ischemia-reperfusion injury. In the heart, studies by Simpson et al.5 (anti-CD11b) and Seewaldt-Becker et al.6 (anti-CD11a, anti-CD18, anti-ICAM-1) were among the first to demonstrate that MAbs directed against either leukocyte or endothelial cell adhesion glycoproteins were effective in limiting the myocardial necrosis that developed in response to an ischemia-reperfusion protocol. Efficacy has also been demonstrated for MAbs administered just before reperfusion directed against the following molecules: L- …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
